Mani Foroohar's questions to Schrodinger Inc (SDGR) leadership • Q3 2024
Question
Mani Foroohar of Leerink Partners inquired if the reduced drug discovery guidance was a timing issue benefiting 2025 and asked about trends in new, smaller customer additions.
Answer
CFO Geoff Porges confirmed the guidance reduction was due to timing uncertainty for milestones expected near year-end, expressing confidence for 2025, which will be bolstered by the Novartis deal. He noted positive inquiry from smaller, private companies but stated they are not yet a significant contributor to growth, as the company's focus remains on scaling up large and mid-sized customers.